Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory securities lawsuit

Regeneron Fianlimab-Libtayo Trial Securities Class Action

Analysis based on 240 articles · First reported Jul 16, 2026 · Last updated Sep 11, 2026

Sentiment
-25
Attention
4
Articles
240
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The litigation reinforces negative sentiment around Regeneron by keeping the failed Fianlimab-Libtayo melanoma trial and the alleged disclosure failures in the headlines, sustaining uncertainty over potential damages and management credibility. Broader market impact is limited and largely idiosyncratic to Regeneron and the biotech sector, though the case adds to the ongoing wave of securities class actions that raise governance and disclosure-risk concerns for large-cap pharmaceutical issuers.

pharmaceuticals biotechnology legal services

Regeneron Pharmaceuticals faces a consolidated securities fraud class action in the U.S. District Court for the Southern District of New York (Cheatham v. Regeneron Pharmaceuticals, Inc., No. 26-cv-06026) filed on behalf of investors who purchased or otherwise acquired Regeneron common stock between August 1, 2025 and May 15, 2026. The complaint alleges that Regeneron and certain of its top executives made materially false and misleading statements and failed to disclose that the preliminary statistical assumptions underlying its Phase III Fianlimab-Libtayo study were fundamentally flawed, that the active treatment arm was not achieving meaningful clinical differentiation over standard therapies, and that the trial was unlikely to reach statistical significance on its primary endpoint even absent overperformance of the control arm. According to the complaint, on April 29, 2026, during Regeneron's first quarter earnings call, the company disclosed that the study protocol had been altered to expand the number of patients eligible for progression-free survival analysis; Regeneron stock fell $45.41, or about 6.2%, to close at $686.36 that day. On May 15, 2026, Regeneron reportedly announced that the Phase 3 trial of Fianlimab did not reach statistical significance for the primary endpoint of improvement in progression-free survival; the stock fell $68.57, or about 9.8%, to close at $629.68 on May 18, 2026. The decline was described as an approximately $11 billion market capitalization wipeout. Multiple national shareholder-rights firms, including Bronstein, Gewirtz & Grossman, LLC, Hagens Berman, Pomerantz LLP, Robbins Geller Rudman & Dowd LLP, Faruqi & Faruqi, The Gross Law Firm, The Schall Law Firm, and DJS Law Group, have issued notices urging investors to seek appointment as lead plaintiff before the September 14, 2026 deadline. The class has not yet been certified.

94 Levi & Korsinsky notified investors of lawsuit Regeneron Pharmaceuticals
90 Regeneron Pharmaceuticals lost market cap
90 Hagens Berman filed securities lawsuit Regeneron Pharmaceuticals
90 Levi & Korsinsky filed securities class action Regeneron Pharmaceuticals
87 Regeneron Pharmaceuticals disclosed trial failure
85 Hagens Berman altered trial protocol
85 Regeneron Pharmaceuticals announced failed endpoint
85 Regeneron Pharmaceuticals admitted slow event rates
85 Regeneron Pharmaceuticals lost market capitalization
80 Regeneron Pharmaceuticals misled investors
80 Regeneron Pharmaceuticals disclosed protocol alteration
+ 34 more actions View on Dashboard
stock
Regeneron is the sole defendant company in the securities class action, accused of misleading investors about the Phase III Fianlimab-Libtayo study. The failed trial and the resulting litigation have erased roughly $11 billion in market capitalization and continue to weigh on investor confidence and management credibility.
Importance 100.0 Sentiment -45.0
priv
BFA Law is reminding investors of the class action deadline. The firm benefits from the litigation.
Importance 30.0 Sentiment 20.0
priv
Bronstein, Gewirtz & Grossman, LLC is one of the lead plaintiffs' firms announcing the class action and soliciting Regeneron investors to seek lead plaintiff appointment before the September 14, 2026 deadline.
Importance 30.0 Sentiment 0.0
priv
Hagens Berman is investigating the claims and alerting Regeneron investors to the pending securities class action, emphasizing the alleged protocol alteration and the $11 billion market cap wipeout.
Importance 30.0 Sentiment 0.0
per
The founding partner of Bronstein, Gewirtz & Grossman, LLC is the named contact announcing the class action against Regeneron.
Importance 25.0 Sentiment 0.0
per
The Hagens Berman partner leads the firm's investigation into whether Regeneron misled investors about the trial protocol.
Importance 25.0 Sentiment 0.0
priv
Pomerantz LLP filed and publicized the class action, detailing the April 29 and May 15, 2026 stock drops tied to the Fianlimab-Libtayo disclosures.
Importance 25.0 Sentiment 0.0
priv
Robbins Geller Rudman & Dowd LLP is counsel in the Cheatham v. Regeneron action and is reminding investors of the September 14, 2026 lead plaintiff deadline.
Importance 25.0 Sentiment 0.0
priv
The firm is soliciting Regeneron stockholders interested in leading the class action and recovering losses.
Importance 20.0 Sentiment 5.0
per
The The Schall Law Firm attorney is the contact urging Regeneron shareholders to participate in the class action.
Importance 20.0 Sentiment 0.0
per
The Pomerantz LLP contact advising Regeneron investors on joining the class action and the lead plaintiff deadline.
Importance 20.0 Sentiment 0.0
per
The DJS Law Group attorney is the contact for shareholders seeking to participate in the Regeneron class action.
Importance 20.0 Sentiment 0.0
priv
Faruqi & Faruqi is investigating potential claims against Regeneron and reminding investors of the lead plaintiff deadline in the federal securities class action.
Importance 20.0 Sentiment 0.0
per
The client relations manager at Bronstein, Gewirtz & Grossman, LLC serves as a contact for Regeneron investors in the class action.
Importance 15.0 Sentiment 0.0
priv
The The Schall Law Firm is reminding investors of the class action against Regeneron for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Importance 15.0 Sentiment 0.0
+ 3 more entities View on Dashboard
BFA Law related ↔ Hagens Berman
BFA Law related ↔ Reed Kathrein
BFA Law related ↔ Pomerantz LLP
BFA Law related ↔ Robbins LLP
BFA Law related ↔ Brian Schall
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Pomerantz LLP Bronstein, Gewirtz & Grossman, LLC frequently acts as co-plaintiff with Pomerantz LLP in numerous securities class actio
Bronstein, Gewirtz & Grossman, LLC co-plaintiffs ↔ Robbins Geller Rudman & Dowd LLP Bronstein, Gewirtz & Grossman, LLC frequently acts as a co-plaintiff with Robbins Geller Rudman & Dowd LLP in numerous s
Bronstein, Gewirtz & Grossman, LLC co-counsel ↔ Robbins LLP Bronstein, Gewirtz & Grossman, LLC frequently acts as co-counsel or co-solicitor with Robbins LLP in various securities
+ 21 more relationships View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.